Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD

Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints

Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome